A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of Ascending Single and Fixed Repeat Intravenous Doses of DMT in Healthy Subjects
Latest Information Update: 29 Apr 2024
At a glance
- Drugs N-N-dimethyltryptamine (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors Algernon Pharmaceuticals
- 24 Apr 2024 According to an Algernon NeuroScience media release, company will present Phase 1 stroke study data at the Interdisciplinary Conference on Psychedelic Research being held June 6-8, 2024 in Haarlem, the Netherlands.
- 03 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Mar 2024.
- 03 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Mar 2024.